化疗和信号传导

泰季 亚娜, 伊利 亚·, 埃里 卡·, 伊戈 尔·
亚利桑那州立大学

摘要

近年来，肿瘤学家已经开始得出结论，即使毒性可以得到有效控制，化疗作为主要治疗方式的疗效也已达
到平台期。新兴的信号通路和代谢通路特异性抑制剂（即靶向药物）与传统化疗药物相比，后者主要干扰DNA生物
合成和细胞复制机制。为了提高疗效，靶向药物与常规化疗药物的组合已成为在早期临床试验中测试多种新药的常
规方法。这篇综述讨论了最近的进展，包括综合系统生物学和RNAi方法来抵消化疗耐药性并支持抗癌药物治疗的
选择性、疗效和个性化。

关键词

化学疗法；耐药性；靶向治疗；RNAi筛选；综合生物学；DNA损伤；合成杀伤力

参考

[1]Gilman A, Philips FS. The biological actions and

therapeutic applications of the B-chloroethyl amines and

sulfides. Science. 1946;103:409–436.

[2]Tallman MS, Gray R, Robert NJ, LeMaistre CF,

Osborne CK, Vaughan WP, et al. Conventional adjuvant

chemotherapy with or without high-dose chemotherapy and

autologous stem-cell transplantation in high-risk breast

cancer. N Engl J Med. 2003;349:17–26.

[3]Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA,

Mangan KF, Ingle JN, et al. Conventional-dose chemotherapy

compared with high-dose chemotherapy plus autologous

hematopoietic stem-cell transplantation for metastatic breast

cancer. Philadelphia Bone Marrow Transplant Group. N Engl J

Med. 2000;342:1069–1076.

[4]Cobo M, Isla D, Massuti B, Montes A, Sanchez JM,

Provencio M, et al. Customizing cisplatin based on quantitative

excision repair cross-complementing 1 mRNA expression: a

phase III trial in non-small-cell lung cancer. J Clin Oncol.

2007;25:2747–2754.

[5]Cohen P. The development and therapeutic potential of

protein kinase inhibitors. Curr Opin Chem Biol. 1999;3:459–

465.

[6]NOWELL PC, HUNGERFORD DA. Chromosome

studies on normal and leukemic human leukocytes. J Natl

Cancer Inst. 1960 Jul;25:85-109.

[7]Huggins C, Hodges CV. Studies on prostatic cancer. I.

The effect of castration, of estrogen and androgen injection on

serum phosphatases in metastatic carcinoma of the prostate.

CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40.

[8]Fisher B, Costantino JP, Wickerham DL, Redmond

CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov

N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark

N. Tamoxifen for prevention of breast cancer: report of the

National Surgical Adjuvant Breast and Bowel Project P-1

Study. J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88.

[9]Baum M, Brinkley DM, Dossett JA, McPherson K,

Patterson JS, Rubens RD, Smiddy FG, Stoll BA, Wilson A, Lea

JC, Richards D, Ellis SH. Improved survival among patients

treated with adjuvant tamoxifen after mastectomy for early

breast cancer. Lancet. 1983 Aug 20;2(8347):450.

[10]McLaughlin P, Grillo-López AJ, Link BK, Levy R,

Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I,

White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen

D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal

antibody therapy for relapsed indolent lymphoma: half of

patients respond to a four-dose treatment program. J Clin

Oncol. 1998 Aug;16(8):2825-33.